Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review

被引：32

作者：

de Ruijter, Tim C. ^{[1
,2
]}

van der Heide, Frank ^{[1
]}

Smits, Kim M. ^{[1
,2
,3
]}

Aarts, Maureen J. ^{[1
,2
]}

van Engeland, Manon ^{[2
,3
]}

Heijnen, Vivianne C. G. ^{[1
,2
]}

机构：

[1] Maastricht Univ, Med Ctr, Div Med Oncol, POB 5800, NL-6202 AZ Maastricht, Netherlands

[2] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol, GROW, NL-6200 MD Maastricht, Netherlands

[3] Maastricht Univ, Med Ctr, Dept Pathol, NL-6202 AZ Maastricht, Netherlands

来源：

BREAST CANCER RESEARCH | 2020年 / 22卷 / 01期

关键词：

Biomarkers; DNA methylation; Breast cancer; Hormone receptor positive; Oestrogen receptor positive; Luminal breast cancer; Prognosis; Promoter CpG island methylation; Survival; BRCA1 PROMOTER METHYLATION; POPULATION-BASED VALIDATION; DISEASE-FREE SURVIVAL; POOR-PROGNOSIS; CLINICAL-SIGNIFICANCE; SERUM DNA; POTENTIAL BIOMARKER; RASSF1A METHYLATION; ENDOCRINE THERAPY; MULTIPLE GENES;

D O I：

10.1186/s13058-020-1250-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In patients with hormone receptor-positive breast cancer, differentiating between patients with a low and a high risk of recurrence is an ongoing challenge. In current practice, prognostic clinical parameters are used for risk prediction. DNA methylation markers have been proven to be of additional prognostic value in several cancer types. Numerous prognostic DNA methylation markers for breast cancer have been published in the literature. However, to date, none of these markers are used in clinical practice. Methods: We conducted a systematic review of PubMed and EMBASE to assess the number and level of evidence of published DNA methylation markers for hormone receptor-positive breast cancer. To obtain an overview of the reporting quality of the included studies, all were scored according to the REMARK criteria that were established as reporting guidelines for prognostic biomarker studies. Results: A total of 74 studies were identified reporting on 87 different DNA methylation markers. Assessment of the REMARK criteria showed variation in reporting quality of the studies. Eighteen single markers and one marker panel were studied in multiple independent populations. Hypermethylation of the markers RASSF1, BRCA, PITX2, CDH1, RARB, PCDH10 and PGR, and the marker panel GSTP1, RASSF1 and RARB showed a statistically significant correlation with poor disease outcome that was confirmed in at least one other, independent study. Conclusion: This systematic review provides an overview on published prognostic DNA methylation markers for hormone receptor-positive breast cancer and identifies eight markers that have been independently validated. Analysis of the reporting quality of included studies suggests that future research on this topic would benefit from standardised reporting guidelines.

引用

页数：12

共 102 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2]

Altman DG, 2012, BMC MED, V10, DOI [10.1186/1741-7015-10-51, 10.1371/journal.pmed.1001216]

[3] CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients [J].

Angelova, S. G. ;

Krasteva, M. E. ;

Gospodinova, Z. I. ;

Georgieva, E. I. .

NEOPLASMA, 2012, 59 (06) :622-630

[4]

[Anonymous], 2015, Global cancer facts figures, V3rd

[5] Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers [J].

Arai, Takashi ;

Miyoshi, Yasuo ;

Kim, Seung Jin ;

Taguchi, Tetsuya ;

Tamaki, Yasuhiro ;

Noguchi, Shinzaburo .

BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (02) :169-176

[6] DNA hypermethylation in tumorigenesis - epigenetics joins genetics [J].

Baylin, SB ;

Herman, JG .

TRENDS IN GENETICS, 2000, 16 (04) :168-174

[7] DNA methylation and gene silencing in cancer [J].

Baylin S.B. .

Nature Clinical Practice Oncology, 2005, 2 (Suppl 1) :S4-S11

[8]

Buhmeida A, 2011, ANTICANCER RES, V31, P2975

[9] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].

Cardoso, F. ;

van't Veer, L. J. ;

Bogaerts, J. ;

Slaets, L. ;

Viale, G. ;

Delaloge, S. ;

Pierga, J. -Y. ;

Brain, E. ;

Causeret, S. ;

DeLorenzi, M. ;

Glas, A. M. ;

Golfinopoulos, V. ;

Goulioti, T. ;

Knox, S. ;

Matos, E. ;

Meulemans, B. ;

Neijenhuis, P. A. ;

Nitz, U. ;

Passalacqua, R. ;

Ravdin, P. ;

Rubio, I. T. ;

Saghatchian, M. ;

Smilde, T. J. ;

Sotiriou, C. ;

Stork, L. ;

Straehle, C. ;

Thomas, G. ;

Thompson, A. M. ;

van der Hoeven, J. M. ;

Vuylsteke, P. ;

Bernards, R. ;

Tryfonidis, K. ;

Rutgers, E. ;

Piccart, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729

[10] BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients [J].

Cerne, Jasmina Z. ;

Zong, Lin ;

Jelinek, Jaroslav ;

Hilsenbeck, Susan G. ;

Wang, Tao ;

Oesterreich, Steffi ;

McGuire, Sean E. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (01) :135-143

← 1 2 3 4 5 6 7 8 9 10 →